Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roderick C N van den Bergh

Showing results (11-20 of 196) with videos related to

Pageof 20
Sort By:
Lancet (London, England)|July 19, 2025
Prostate radiotherapy in PEACE-1: is the event worth the treatment?Robert J van Soest, Roderick C N van den Bergh
European Urology|January 14, 2014
Re: M. Minhaj Siddiqui, Soroush Rais-Bahrami, Hong Truong, et al. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol 2013;64:713-9 and Re: Mark Emberton. Has magnetic resonance-guided biopsy of the prostate become the standard of care? Eur Urol 2013;64:720-1Roderick C N van den Bergh, Henk G van der Poel
European Urology Focus|July 21, 2017
Impact of Early Diagnosis of Prostate Cancer on Survival OutcomesRoderick C N van den Bergh, Stacy Loeb, Monique J Roobol
International Braz J Urol : Official Journal of the Brazilian Society of Urology|June 11, 2016
Difference of opinion - Active surveillance in intermediate risk prostate cancer: is it safe? Opinion: YesHenk G van der Poel, Roderick C N van den Bergh
European Urology|June 16, 2016
Re: Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate SurgeryRoderick C N van den Bergh, Homayoun Zargar, Declan G Murphy
The Journal of Urology|June 24, 2020
Editorial CommentRoderick C N van den Bergh, Henk G van der Poel
European Urology|April 19, 2020
Re: Timothy J. Wilt, Tien N. Vo, Lisa Langsetmo, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.02.009Roderick C N van den Bergh, Massimo Valerio, Derya Tilki, et al.
European Urology|September 26, 2024
Standard Repeat Biopsies During Active Surveillance for Prostate Cancer: Are They Necessary in the Magnetic Resonance Imaging Era?Roderick C N van den Bergh, Ivo G Schoots, Philip A Cornford, et al.
European Urology|July 15, 2020
Re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol 2020;78:304-6: Prebiopsy MRI: Through the Looking GlassRoderick C N van den Bergh, Olivier Rouvière, Theodorus van der Kwast, et al.
Current Opinion in Urology|February 19, 2015
Identification of candidates for observationRoderick C N van den Bergh, Declan G Murphy, Anthony J Costello
Pageof 20

Showing results (11-20 of 196) with videos related to

Sort By:
Pageof 20
Lancet (London, England)|July 19, 2025
Prostate radiotherapy in PEACE-1: is the event worth the treatment?Robert J van Soest, Roderick C N van den Bergh
European Urology|January 14, 2014
Re: M. Minhaj Siddiqui, Soroush Rais-Bahrami, Hong Truong, et al. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol 2013;64:713-9 and Re: Mark Emberton. Has magnetic resonance-guided biopsy of the prostate become the standard of care? Eur Urol 2013;64:720-1Roderick C N van den Bergh, Henk G van der Poel
European Urology Focus|July 21, 2017
Impact of Early Diagnosis of Prostate Cancer on Survival OutcomesRoderick C N van den Bergh, Stacy Loeb, Monique J Roobol
International Braz J Urol : Official Journal of the Brazilian Society of Urology|June 11, 2016
Difference of opinion - Active surveillance in intermediate risk prostate cancer: is it safe? Opinion: YesHenk G van der Poel, Roderick C N van den Bergh
European Urology|June 16, 2016
Re: Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate SurgeryRoderick C N van den Bergh, Homayoun Zargar, Declan G Murphy
The Journal of Urology|June 24, 2020
Editorial CommentRoderick C N van den Bergh, Henk G van der Poel
European Urology|April 19, 2020
Re: Timothy J. Wilt, Tien N. Vo, Lisa Langsetmo, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.02.009Roderick C N van den Bergh, Massimo Valerio, Derya Tilki, et al.
European Urology|September 26, 2024
Standard Repeat Biopsies During Active Surveillance for Prostate Cancer: Are They Necessary in the Magnetic Resonance Imaging Era?Roderick C N van den Bergh, Ivo G Schoots, Philip A Cornford, et al.
European Urology|July 15, 2020
Re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol 2020;78:304-6: Prebiopsy MRI: Through the Looking GlassRoderick C N van den Bergh, Olivier Rouvière, Theodorus van der Kwast, et al.
Current Opinion in Urology|February 19, 2015
Identification of candidates for observationRoderick C N van den Bergh, Declan G Murphy, Anthony J Costello
Pageof 20